ACBM Reports Zero Revenue, Issues 60M Shares for Services
Ticker: ACBM · Form: 10-Q · Filed: Jul 11, 2025 · CIK: 1622996
| Field | Detail |
|---|---|
| Company | Acro Biomedical CO., LTD. (ACBM) |
| Form Type | 10-Q |
| Filed Date | Jul 11, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Biomedical, Zero Revenue, Stock Dilution, High Risk, SEC Filing, Penny Stock, Customer Concentration
Related Tickers: ACBM
TL;DR
**ACBM is a non-starter with zero revenue and massive stock dilution; avoid.**
AI Summary
ACRO BIOMEDICAL CO., LTD. (ACBM) reported no revenue for the nine months ended September 30, 2023, consistent with the prior year, indicating a lack of operational sales. The company also reported no net income or loss for the period. Key business changes include the issuance of 60,042,000 shares of common stock to a stockholder for services rendered during the three and nine months ended September 30, 2023, valued at $0.001 per share, totaling $60,042. This issuance significantly increased outstanding common stock. A primary risk highlighted is customer concentration, with Customer A and Customer B accounting for 100% of revenue in 2021, and the company having no revenue in 2023. The strategic outlook remains unclear given the absence of revenue and ongoing reliance on stock issuances for compensation. The company also noted a lease agreement in Hong Kong from November 1 to November 3, 2021, but no current operational leases were detailed for 2023.
Why It Matters
ACBM's continued lack of revenue and reliance on stock-based compensation for services raises significant red flags for investors, suggesting a company struggling to establish a viable business model. The issuance of 60,042,000 shares to a single stockholder dilutes existing shareholder value and indicates a potential lack of cash flow for operational expenses. This financial instability could deter potential customers and employees, making it difficult for ACBM to compete in the biomedical sector. Without a clear path to revenue generation, the broader market may view ACBM as a speculative venture with high risk.
Risk Assessment
Risk Level: high — The risk level is high due to ACBM reporting $0 revenue for the nine months ended September 30, 2023, and the issuance of 60,042,000 shares of common stock to a stockholder for services, valued at $60,042. This indicates a lack of operational income and significant shareholder dilution without corresponding business growth.
Analyst Insight
Investors should avoid ACBM given the complete absence of revenue and the substantial dilution from issuing 60,042,000 shares for services. This filing suggests the company lacks a sustainable business model and presents an extremely high-risk investment.
Financial Highlights
- debt To Equity
- 0.0
- revenue
- $0
- operating Margin
- N/A
- total Assets
- $0
- total Debt
- $0
- net Income
- $0
- eps
- $0.00
- gross Margin
- N/A
- cash Position
- $0
- revenue Growth
- N/A
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Total Revenue | $0 | N/A |
Key Numbers
- $0 — Revenue (for the nine months ended September 30, 2023, indicating no sales)
- 60,042,000 — Common Stock Shares Issued (issued to a stockholder for services, causing significant dilution)
- $0.001 — Per Share Value (of common stock issued for services)
Key Players & Entities
- ACRO BIOMEDICAL CO., LTD. (company) — filer of the 10-Q
- Customer A (company) — accounted for 100% of revenue in 2021
- Customer B (company) — accounted for 100% of revenue in 2021
- Hong Kong (location) — location of a past lease agreement
- $0.001 (dollar_amount) — per share value of common stock issued
- $60,042 (dollar_amount) — total value of common stock issued for services
FAQ
What was ACRO BIOMEDICAL CO., LTD.'s revenue for the nine months ended September 30, 2023?
ACRO BIOMEDICAL CO., LTD. reported $0 in revenue for the nine months ended September 30, 2023, indicating no sales activity during this period.
How many shares did ACBM issue for services during Q3 2023?
ACBM issued 60,042,000 shares of common stock to a stockholder for services rendered during the three and nine months ended September 30, 2023.
What was the value of the common stock issued by ACBM for services?
The common stock issued by ACBM for services was valued at $0.001 per share, totaling $60,042 for the 60,042,000 shares.
Does ACRO BIOMEDICAL CO., LTD. have customer concentration risk?
Yes, ACRO BIOMEDICAL CO., LTD. has significant customer concentration risk, as Customer A and Customer B accounted for 100% of its revenue in 2021, and the company reported no revenue in 2023.
What is the strategic outlook for ACBM given its current financial state?
The strategic outlook for ACBM is unclear, as the company has no reported revenue and relies on stock issuances for compensation, suggesting a lack of a sustainable operational strategy.
What impact does the stock issuance have on ACBM investors?
The issuance of 60,042,000 shares of common stock to a single stockholder significantly dilutes the ownership percentage of existing ACBM investors.
Did ACBM report any net income or loss for the nine months ended September 30, 2023?
ACBM reported no net income or loss for the nine months ended September 30, 2023, consistent with its lack of revenue.
Where is ACRO BIOMEDICAL CO., LTD.'s business address?
ACRO BIOMEDICAL CO., LTD.'s business address is 12175 Visionary Way, Suite 1160, Fishers, IN 46038.
What was ACBM's former company name?
ACBM's former company name was KILLER WAVES HAWAII, INC., with the name change occurring on October 22, 2014.
What is the primary concern for regulators regarding ACBM's filing?
A primary concern for regulators might be the lack of operational revenue and the significant stock issuance for services, which could raise questions about the company's viability and potential for market manipulation.
Risk Factors
- Customer Concentration [high — operational]: The company faces extreme customer concentration risk, with Customers A and B accounting for 100% of revenue in 2021. As of September 30, 2023, the company reported no revenue, indicating a complete loss of these key customers or a cessation of operations.
- Reliance on Stock Issuance for Compensation [high — financial]: The company issued 60,042,000 shares of common stock for services rendered during the nine months ended September 30, 2023, valued at $0.001 per share, totaling $60,042. This indicates a lack of cash to compensate services and significant dilution for existing shareholders.
- Lack of Operational Sales [high — operational]: ACBM reported no revenue for the nine months ended September 30, 2023, and no net income or loss. This suggests a complete halt in business operations or an inability to generate sales, raising serious concerns about the company's viability.
Industry Context
ACRO BIOMEDICAL CO., LTD. operates within the broader biomedical or healthcare services sector, which is typically characterized by innovation, regulatory oversight, and significant capital requirements. However, given ACBM's reported lack of revenue and reliance on stock for compensation, its specific competitive positioning and industry trends are unclear. The company's SIC code (7900 - Amusement & Recreation Services) appears to be a misclassification given its name.
Regulatory Implications
While no specific regulatory issues are detailed, the lack of revenue and reliance on stock for services could attract scrutiny from regulatory bodies regarding the valuation of services and the nature of compensation. Companies with no operational revenue are often subject to delisting reviews by stock exchanges.
What Investors Should Do
- Seek clarification on business operations and revenue generation strategy.
- Evaluate the long-term impact of stock-based compensation on dilution.
- Assess the company's financial viability and cash runway.
Key Dates
- 2021-11-01: Lease agreement in Hong Kong commenced — Indicates past operational presence, but no current leases are detailed for 2023.
- 2023-09-30: Nine months ended period for 10-Q filing — Reporting period showing $0 revenue and significant stock issuance for services.
Glossary
- Customer Concentration Risk
- A risk that arises when a company relies heavily on a small number of customers for its revenue. The loss of any of these key customers could have a significant negative impact on the company's financial performance. (ACBM's historical revenue was 100% dependent on two customers, highlighting a critical vulnerability.)
- Deferred Stock Compensation
- Compensation paid to employees or service providers in the form of stock that is subject to vesting or other restrictions over time. It is recognized as an expense over the period the services are rendered. (The company issued a large number of shares for services, impacting equity and potentially future earnings.)
- Common Stock Shares Issued
- The number of shares of the company's ownership stock that have been distributed to shareholders or for other purposes. (A significant increase in shares issued for services indicates dilution and a lack of cash for compensation.)
Year-Over-Year Comparison
The company reported $0 revenue for the nine months ended September 30, 2023, consistent with the prior year's period, indicating no improvement in sales generation. Net income also remained at $0. A significant change is the issuance of 60,042,000 common shares for services, which represents a substantial increase in outstanding stock and potential dilution compared to previous periods where such large stock issuances for services were not highlighted.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on July 11, 2025 regarding ACRO BIOMEDICAL CO., LTD. (ACBM).